Did you miss these recent slide/audio lectures?
Hepatitis C and Renal Disease

Roy D. Bloom, MD and Robert S. Brown, Jr, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Bloom: What are the characteristics of transplant candidates infected with hepatitis C? What is the impact of HCV infection on patient and graft survival?
On hepatic complications? On new onset diabetes (NODAT)? Glomerulonephritis? Infection? Does liver disease progress after transplantation? What is the role of pretransplant interferon? What are useful patient management algorithms? Brown: What are the goals of antiviral therapy of HCV? How durable is a sustained virologic response? How is this affected by duration of interferon therapy and dosage of ribavirin? How is treatment different in genotype 1 vs. 2 and 3 disease? What should be the virologic monitoring strategy? What are issues of using interferon and especially, ribavirin, when renal function is decreased? What are the complications? What is the data with emerging therapies for HCV, including polymerase and proteinase inhibitors? What is the role of triple therapy? Re-treatment?
Primary Care for Nephrologists: HIV Nephropathy

Arthur H. Cohen, MD; and Jeffrey S. Berns, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Cohen: What are the nephropathies directly related to HIV infection? How have they changed in the era of HAART? What happened to the tubuloreticular inclusions? Tubular microcystic dilatation? ATN-like lesions? What about those related to complications of HIV? How does the immune complex-like lesion relate to HIV infection? What is the pathogenesis of the lupus-like lesions in HIV? What characterizes indinavir and tenofovir nephrotoxicities? Dr. Berns: What are the pitfalls of assessing GFR in patients with HIV? Why should cystatin estimates be avoided? What has follow-up data been on efficacy of ACE inhibitors and HIVAN? Under which conditions, if any, might corticosteroid treatment be considered? How does one approach TTP/TMA in HIV-infected patients? Are there any substantial access-related issues in hemodialysis patients with HIV?

ASN Renal Week 2009 now in MP3
 |
AUDIOFILE
LIST (ASN Renal Week 2009)
(52 talks)
Is Peritoneal Dialysis Membrane Failure Inevitable with Long-term Use?
A. Breborowicz, W Van Biesen, S. K. Mujais, and B. Lindholm
Important Clinical Trials in Transplantation
H. Ekberg, F. G. Vincenti, J. D. Schold, and S. M. Flechner
Diabetic Nephropathy
A. K. Mottl, M. E. Williams, J. Lewis, and K. R. Tuttle
Update in Acute Kidney Injury (AKI)
S. S. Waikar, P. W. Eggers, S. Goldstein, and P. M. Palevsky
The Importance of Proteinuria as a Surrogate for Outcome in CKD
T. H. Hostetter, A. M. Thompson, G. Remuzzi, D. De Zeeuw and T. H. Greene
Quotidian (Daily) Dialysis
A. S. Kliger, C. T. Chan, M. L. Unruh, and B. J. Manns
Nephrology Quiz & Questionnaire
J. M. Bargman, B. F. Palmer, M. D. Samaniego-Picota, and F. C. Fervenza
Glomerular Injury in Progressive Renal Disease
S. G. Adler, J. C. Jennette, E. Ritz, and J. F. Bertram
Debates in Renal Disease 2: Combination of ACEI and ARB is More Efficacious than Monotherapy
H. Paraving, and J. F. Mannr
Vascular Calcification
S. E. Rosas, P. Raggi, M. J. Budoff, and M. Ketteler
Thrombotic Microangiopathies
J. E. Sadler, G. B. Appel, W. F. Clark, and C. Licht
The Changing Face of FSGS/MCD
M. Kretzler, J. Radhakrishnan, D. C. Cattran, and J. B. Kopp
Infectious Risk in Renal Replacement Therapy
N. D. Vaziri, A. J. Collins, N. R. Powe, and C. E. Lok
|
|